Skip to Main Content

INFORMATION FOR

Preston C. Sprenkle, MD

Associate Professor of Urology; Co-Chair, Cancer Liaison Committee, Oncology; Co-Chair, NCCN Guidelines Committee on Prostate Cancer Early Detection; Division Chief, Division of Urology at VA Connecticut Healthcare System, Urology; Director, Urology Research Fellowship, Urology; Director, Urologic Oncology Clinical Fellowship Program, Urology

Appointments

Biography

Dr. Preston C. Sprenkle specializes in the treatment of urologic cancers, including prostate cancer, kidney cancer, bladder cancer, testicular cancer and sarcoma – a rare kind of cancer that grows in cells that connect or support other parts of the body, like bone or muscle.

Dr. Sprenkle has dedicated his career to using the latest imaging technologies to improve diagnosis. He was one of the first physicians nationwide to implement the use of the Artemis Device. This machine, introduced in 2009, allows a surgeon to use 3D ultrasound technology and merge it with even more precise magnetic resonance imaging (MRI) to accurately identify cancerous tumors.

“Skilled and experienced radiologists are rare for this relatively new technique,” Dr. Sprenkle explains. “At Yale, we are fortunate to have some of the world leaders in prostate MRI.”

Dr. Sprenkle is also a pioneer in “focal therapy,” which allows a surgeon to treat tiny prostate lesions, rather than the whole organ. This avoids many of the side effects—such as erectile dysfunction and incontinence—that may follow the removal of the whole prostate.

“Exciting technological advances are revolutionizing urology. Prostate cancer is very common and current treatments can majorly impact a man's sexual and urinary function,” Dr. Sprenkle says. “Developing ways to minimize the impact of prostate cancer diagnosis and treatment on a man's health and quality of life is tremendously rewarding.”

Dr. Sprenkle believes in working with patients to come up with individualized treatment plans. “I want my patients to feel that I hear their concerns and treat them like a person. I am pleased at the end of a long consultation when they feel like they understand their disease and their options.”

Education & Training

  • Non Degree Program
    Yale School of Management, Emerging Leaders Program (2018)
  • Fellowship
    Memorial Sloan Kettering Cancer Center (2011)
  • Residency
    New York Presbyterian Hospital (2009)
  • Internship
    New York Presbyterian Hospital (2005)
  • MD
    Columbia University (2004)
  • BA
    Stanford University, Human Biology (1998)

Activities

  • New Treatments in Prostate Cancer, the TULSA Pro
    Participated in virtual support group for men with prostate cancer on the East Coast of the United States 2022
    Men Fighting Cancer Prostate Cancer support group
  • Experience with PET imaging
    https://www.docwirenews.com/round-the-wire-gu/ 2022
    ASCO GU 2022: Key Takeaways in Prostate Cancer Imaging
  • Prostate cancer outcomes, comparing surgery and radiation. Side effects of robotic prostatectomy
    AIS Channel Live Surgery 2022
    Prostate Caner Surgery versus Radiotherapy, the Current State of the Art
  • Negative Multiparametric MRI of the Prostate: can biopsy be avoided?
    Vienna, Vienna, Austria 2021
    European Society of Medicine Annual Congress
  • Update on NCCN Early Detection of Prostate Cancer Guidelines
    Boston, MA, United States 2021
    5th Annual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer
  • Roundtable discussion on PSMA PET/CT imaging in prostate cancer
    Presentations available online through AUA 2021 2021
    American Urological Association Annual Meeting
  • How to: Prostate Ultrasound
    Created instructional Video for AUA Educational Series 2021
    How to: Prostate Ultrasound
  • How To: Placement of Endorectal Spacer and Fiducial Markers
    Created instructional Video for AUA Educational Series 2021
    How To: Placement of Endorectal Spacer and Fiducial Markers
  • Negative prostate MRI, can prostate biopsy be avoided?
    Vienna, Vienna, Austria 2021
    Negative prostate MRI, can prostate biopsy be avoided?
  • Diagnostic Test for Early Detection of Prostate Cancer, review of NCCN Guidelines update
    Fourth Global Summit on Precision Diagnosis for Prostate Cancer 2020
    Diagnostic Test for Early Detection of Prostate Cancer, review of NCCN Guidelines update
  • Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates
    Boston, MA, United States 2019
    Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates
  • Integrating a rectal spacer procedure into urology practice
    Chicago, IL, United States 2019
    Integrating a rectal spacer procedure into urology practice
  • Prostate Cancer Session Moderator
    Providence, RI, United States 2019
    Prostate Cancer Session Moderator
  • Multimodal treatment of advanced prostate cancer, discussion panel member
    Providence, RI, United States 2019
    Multimodal treatment of advanced prostate cancer, discussion panel member
  • Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates
    Boston, MA, United States 2018
    Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates
  • Hands On Training Course, MR-US fusion prostate biopsy tips and tricks
    San Francisco, CA, United States 2018
    Hands On Training Course, MR-US fusion prostate biopsy tips and tricks
  • Session Moderator: Prostate cancer genomics panel
    Hartford, CT, United States 2018
    Session Moderator: Prostate cancer genomics panel
  • Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates
    Boston, MA, United States 2017
    Diagnostic Tests for Early Detection of Prostate Cancer, review of NCCN guidelines updates
  • MR-US Fusion Biopsy, West Haven VA experience
    Boston, MA, United States 2017
    MR-US Fusion Biopsy, West Haven VA experience
  • Principles of Image Registration
    Linthicum Heights, MD, United States 2017
    Principles of Image Registration
  • MR-US fusion biopsy in practice: Yale University experience
    Linthicum Heights, MD, United States 2017
    MR-US fusion biopsy in practice: Yale University experience
  • Yale experience with SpaceOAR rectal spacer
    Montreal, QC, Canada 2017
    Yale experience with SpaceOAR rectal spacer
  • Outcomes of Serial MRI-Fusion Biopsy in Men with Prostate Cancer Managed with Active Surveillance
    Boston, MA, United States 2017
    Outcomes of Serial MRI-Fusion Biopsy in Men with Prostate Cancer Managed with Active Surveillance
  • Physician learning curve using MR-US fusion prostate biopsy
    Montreal, QC, Canada 2017
    Physician learning curve using MR-US fusion prostate biopsy
  • Image Registration in MR-US Fusion biopsy
    Chicago, IL, United States 2016
    Image Registration in MR-US Fusion biopsy
  • Focal ablation for prostate cancer
    Portland, ME, United States 2016
    Focal ablation for prostate cancer
  • Should we still biopsy patients with a negative MP-MRI?
    San Diego, CA, United States 2016
    Should we still biopsy patients with a negative MP-MRI?
  • Emerging role of MR-US fusion prostate biopsy
    Hartford, CT, United States 2015
    Emerging role of MR-US fusion prostate biopsy
  • MR-US Fusion prostate biopsy: improving prostate cancer diagnosis
    West Haven, CT, United States 2015
    MR-US Fusion prostate biopsy: improving prostate cancer diagnosis
  • Prostate Cancer Screening
    West Haven, CT, United States 2015
    Prostate Cancer Screening
  • MRI targeted biopsy alone is inadequate to detect clinically significant prostate cancer: a meta-analysis.
    Nassau, New Providence, Bahamas 2015
    MRI targeted biopsy alone is inadequate to detect clinically significant prostate cancer: a meta-analysis.
  • MRI-Fusion biopsy in a first-time biopsy cohort yields increased detection of clinically significant cancer using a simplified MRI grading scale.
    Orlando, FL, United States 2015
    MRI-Fusion biopsy in a firt-time biopsy cohort yields increased detection of clinically significant cancer using a simplified MRI grading scale.
  • MRI-US fusion prostate biopsy, improving cancer detection
    Providence, RI, United States 2014
    MRI-US fusion prostate biopsy, improving cancer detection
  • Urine Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as a marker for Acute Kidney Injury in Kidney Surgery Patients
    Bethesda, MD, United States 2012
    Urine Neutrophil Gelatinase-Associated Lipocalin (uNGAL) as a marker for Acute Kidney Injury in Kidney Surgery Patients
  • Grand Round Presentation "Management of T1 Bladder Cancer"
    Brooklyn, NY, United States 2011
    Grand Round Presentation "Management of T1 Bladder Cancer"
  • Annual Meeting, Society of Urologic Oncology "B7x is a seum marker for prostate cancer."
    Bethseda, MD, United States 2009
    Annual Meeting, Society of Urologic Oncology "B7x is a seum marker for prostate cancer."
  • B7x is a serum marker for prostate cancer
    Bethesda, MD, United States 2009
    B7x is a serum marker for prostate cancer
  • Annual Meeting, American Urological Association, "The bladder trigone is not a Wolffian duct remnant."
    San Francisco, CA, United States 2006
    Annual Meeting, American Urological Association, "The bladder trigone is not a Wolffian duct remnant."
  • The bladder trigone is not a Wolffian duct remnant
    San Francisco, CA, United States 2006
    The bladder trigone is not a Wolffian duct remnant

Honors & Recognition

AwardAwarding OrganizationDate
2021 Thesis Reviewer, PA Master Thesis Committee, Yale School of Medicine2021
Mentor Appreciation AwardInterprofessional Longitudinal Clinical Experience2017, 2018, 2019, 2020
Best Poster Podium PresentationYoung Urologic Oncologist dinner, Society Of Urologic Oncology Annual Meeting2009
Finalist - NY section AUA Valentine Essay ContestNY Academy of Medicine2009
Finalist - NY section AUA Valentine Essay ContestNY Academy of Medicine2007
First Prize - NY section AUA Valentine Essay ContestNY Academy of Medicine2006
Arnold P. Gold Humanism in Medicine Honors Society2004
Alpha Omega Alpha Medical School Honors Society2004
Outstanding Member of Stanford CommunityStanford University1998
Member, Board of DirectorsStanford University Alumni Association1997

Professional Service

OrganizationRoleDate
Clinical Advisory Board, Profound MedicalBoard Member2022 - 2023
NCCN Prostate Cancer Early Detection Guideline PanelVice Chair2021 - Present
Department of Urology Medical Student Thesis review committeeMember2021 - 2023
VHA National Surgery Office - Robotic Surgery Surgical Advisory BoardMember2021 - Present
NIHAd Hoc reviewer for NIH Clinical Trials Genitourinary Steering Committee2019
Scientific Advisory Board, Boston Scientific Inc.Scientific review and advice on urologic products2019 - Present
MCIC LLCSurgeon representative on multi-institutional meetings to improve clinical outcomes2018 - Present
Department of Urology Executive CommitteeMember2016 - Present
Urologic OncologyReviewer2016 - Present
OncotargetReviewer2016 - Present
Nature Scientific ReportsReviewer2016 - Present
Department of Urology Residency Promotion CommitteeMember2015 - 2019
Yale Prostate SPORE kickoff meetingPlanning Committee2015
Yale Interdisciplinary Prostate ProgramInterdisciplinary group focused on collaborative research and development of clinical programs in prostate cancer2015 - Present
Yale Urology Prostate Cancer Screening ClinicParticipant2015 - Present
Clinical Genitourinary CancerReviewer2015 - Present
PLOS OneReviewer2015 - Present
FrontiersAssociate Editor2015 - Present
NCCN Prostate Cancer Early Detection Guideline PanelBoard Member2014 - 2021
Urologic Clinical Cost and Value CommitteeMember2014 - 2016
Interventional Radiology Purchasing CommitteeExpert Panel Member2014 - 2016
Society of Urologic OncologyMember2009 - Present
Journal of UrologyReviewer2009 - Present
Frontiers in ScienceReviewer2009 - Present
UrologyReviewer2009 - Present
Washington Heights free prostate cancer education and screening clinicParticipant2008
American Association of Clinical UrologistsMember2006 - Present

Departments & Organizations